11:26 AM EDT, 08/13/2025 (MT Newswires) -- Stoke Therapeutics ( STOK ) reported "impressive" three-year open-label extension results for its experimental drug zorevunersen, showing sustained seizure reductions and cognitive gains in patients with Dravet syndrome, a severe form of epilepsy, Wedbush said Wednesday in a report.

With "strong" durability results in hand, Stoke plans to meet with the US Food and Drug Administration in H2 to explore options for expediting approval of zorevunersen, which has Breakthrough Therapy Designation, Wedbush said.

Stoke Therapeutics ( STOK ) on Tuesday reported a Q2 loss that narrowed from a year earlier, surprising analysts, as revenue topped estimates, and "management reiterated cash runway guidance with $355 million in cash/equivalents, providing runway into mid-2028," Wedbush said.

Wedbush maintained its outperform rating on Stoke Therapeutics ( STOK ) stock and raised its price target to $22 from $16, citing prosects for a faster zorevunersen launch.

Stoke Therapeutics ( STOK ) shares jumped 19% in recent Wednesday trading.

Price: 16.04, Change: +2.51, Percent Change: +18.55